Lahey Hospital and Medical Center

Running trials

• Recruiting

  Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001

  NCT07867288· Phase 1· Haya Therapeutics, Inc.· Source

• Recruiting

  A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

  NCT07743164· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

  NCT07776691· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

  NCT07383441· Phase 3· SWOG Cancer Research Network· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

  NCT06769126· Phase 2· SWOG Cancer Research Network· Source

• Active, not recruiting

  Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

  NCT06732401· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

  NCT07000084· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

  NCT06872684· Stryker Neurovascular· Source

• Recruiting

  Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  NCT06616584· Phase 2/3· SWOG Cancer Research Network· Source

• Recruiting

  Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer

  NCT06517901· Albany Medical College· Source

• Recruiting

  Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  NCT06498635· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

  NCT06826196· Phase 1/2· Aldena Therapeutics· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

  NCT07187063· Lahey Clinic· Source

• Active, not recruiting

  Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

  NCT06632327· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  NCT06116682· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  NCT06649110· Phase 1/2· Novartis Pharmaceuticals· Source

• Recruiting

  Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  NCT06317649· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  NCT05554406· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  NCT05554393· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  NCT06031688· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

  NCT06205485· Phase 3· Canadian Cancer Trials Group· Source

• Active, not recruiting

  A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

  NCT06347159· Phase 2· Edgewise Therapeutics, Inc.· Source

• Recruiting

  Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Impairments That Affect Correct Inhaler Use in COPD

  NCT06135324· COPD Foundation· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Hamilton Health Sciences Corporation· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

• Recruiting

  International Registry of Intra-arterial and Endosaccular Flow Diverters (IRF)

  NCT06174727· Montefiore Medical Center· Source

• Recruiting

  Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

  NCT05929768· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

  NCT05633602· Phase 3· SWOG Cancer Research Network· Source

• Recruiting

  Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  NCT05327686· Phase 2· NRG Oncology· Source

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

  NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· Phase 2/3· NRG Oncology· Source

• Recruiting

  Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

  NCT05058651· Phase 2/3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)

  NCT05368259· Allurion Technologies· Source

• Active, not recruiting

  Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT05096663· Phase 2/3· SWOG Cancer Research Network· Source

• Recruiting

  myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

  NCT05204888· Temple University· Source

• Active, not recruiting

  Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

  NCT05050084· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

  NCT04835506· Phase 4· Beth Israel Deaconess Medical Center· Source

• Active, not recruiting

  Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT04625647· Phase 2· SWOG Cancer Research Network· Source

• Active, not recruiting

  A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

  NCT04736706· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

  NCT04484818· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

  NCT04586231· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

  NCT03127267· Phase 3· AB Science· Source

• Active, not recruiting

  Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

  NCT04310020· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  NCT04181060· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

  NCT04408625· Phase 1/2· Prevail Therapeutics· Source

• Active, not recruiting

  Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

  NCT04496739· SWOG Cancer Research Network· Source

Showing 50 of 116.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer7 recruiting
• Bladder cancer5 recruiting
• Kidney cancer3 recruiting
• Ovarian cancer3 recruiting
• ALS (motor neurone disease)2 recruiting
• Brain aneurysm2 recruiting
• Colorectal cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Neuroendocrine tumours2 recruiting
• Prostate cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Childhood cancers1 recruiting
• COPD1 recruiting
• Endometrial cancer1 recruiting
• High blood pressure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Multiple sclerosis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Terminated

  Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation

  NCT06364215· Jorge Romero· Source

• Recruiting

  A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

  NCT06012240· Phase 3· AbbVie· Source

• Completed

  Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor

  NCT05216250· Phase 2· AbbVie· Source

• Completed

  A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

  NCT04929379· Phase 2· Alessandro Doria· Source

• Completed

  Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening

  NCT04968548· Nucleix Ltd.· Source

• Completed

  A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

  NCT04809363· Phase 4· Takeda· Source

• Completed

  Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

  NCT04173507· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· Phase 2· SWOG Cancer Research Network· Source

• Terminated

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  High Definition Colonoscopy (HDC) vs. Dye Spraying Chromo-colonoscopy (DSC) in Screening Patients With Long-standing Inflammatory Bowel Disease (IBD)

  NCT04191655· Beth Israel Deaconess Medical Center· Source

• Completed

  Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

  NCT03382561· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

  NCT03258554· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

  NCT03048825· Phase 3· Population Health Research Institute· Source

• Completed

  S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  NCT03365882· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

  NCT03033576· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

  NCT02595905· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer

  NCT02635009· Phase 2/3· NRG Oncology· Source

• Completed

  S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

  NCT02438722· Phase 2/3· SWOG Cancer Research Network· Source

• Completed

  Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

  NCT02364557· Phase 2/3· NRG Oncology· Source

• Completed

  Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

  NCT02254278· Phase 2· NRG Oncology· Source

• Completed

  Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

  NCT01824875· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Completed

  S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

  NCT01809691· Phase 3· SWOG Cancer Research Network· Source

• Completed

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

  NCT01167712· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

  NCT01013649· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

  NCT00861705· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· ETOP IBCSG Partners Foundation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Hypertrophic cardiomyopathy54 works · 2 trials
• Alopecia areata21 works · 2 trials
• Pulmonary arterial hypertension20 works · 1 trial
• Gastroparesis3 works · 0 trials